WO2026042013A1 - Thérapie mitochondriale - Google Patents

Thérapie mitochondriale

Info

Publication number
WO2026042013A1
WO2026042013A1 PCT/IB2025/058371 IB2025058371W WO2026042013A1 WO 2026042013 A1 WO2026042013 A1 WO 2026042013A1 IB 2025058371 W IB2025058371 W IB 2025058371W WO 2026042013 A1 WO2026042013 A1 WO 2026042013A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
mitochondria
engineered
binder
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2025/058371
Other languages
English (en)
Inventor
Temurkhan AYUPOV
Botond Miklós Roska
Verónica de la Santísima Faz MORENO JUAN
Simon Theodor HANSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Molecular And Clinical Ophthalmology Basel Iob
Original Assignee
Institute Of Molecular And Clinical Ophthalmology Basel Iob
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Molecular And Clinical Ophthalmology Basel Iob filed Critical Institute Of Molecular And Clinical Ophthalmology Basel Iob
Publication of WO2026042013A1 publication Critical patent/WO2026042013A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgation concerne des compositions et des procédés de transplantation mitochondriale dans des cellules souhaitées. Les liants moléculaires et les procédés décrits dans la description peuvent assurer une administration ciblée de type cellulaire et une transplantation de mitochondries avec une efficacité et une spécificité accrues.
PCT/IB2025/058371 2024-08-19 2025-08-18 Thérapie mitochondriale Pending WO2026042013A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463684592P 2024-08-19 2024-08-19
US63/684,592 2024-08-19
US202463711933P 2024-10-25 2024-10-25
US63/711,933 2024-10-25

Publications (1)

Publication Number Publication Date
WO2026042013A1 true WO2026042013A1 (fr) 2026-02-26

Family

ID=97026404

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2025/058370 Pending WO2026042012A1 (fr) 2024-08-19 2025-08-18 Anticorps à domaine unique et polypeptides les contenant
PCT/IB2025/058371 Pending WO2026042013A1 (fr) 2024-08-19 2025-08-18 Thérapie mitochondriale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2025/058370 Pending WO2026042012A1 (fr) 2024-08-19 2025-08-18 Anticorps à domaine unique et polypeptides les contenant

Country Status (1)

Country Link
WO (2) WO2026042012A1 (fr)

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5122368A (en) 1988-02-11 1992-06-16 Bristol-Myers Squibb Company Anthracycline conjugates having a novel linker and methods for their production
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5824805A (en) 1995-12-22 1998-10-20 King; Dalton Branched hydrazone linkers
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO2003076567A2 (fr) 2002-03-05 2003-09-18 Eli Lilly And Company Proteines hybrides g-csf heterologues
WO2004010957A2 (fr) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
WO2005077042A2 (fr) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060024317A1 (en) 2004-05-19 2006-02-02 Medarex, Inc Chemical linkers and conjugates thereof
US20130266570A1 (en) * 2012-03-30 2013-10-10 Richard H. Weisbart Targeting Intracellular Target-binding Determinants with Intracellular Antibodies
US20200181578A1 (en) 2018-10-09 2020-06-11 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
EP3786177A1 (fr) * 2018-04-26 2021-03-03 Paean Biotechnology Inc. Mitochondries modifiée et utilisation associée
US11015210B2 (en) 2013-03-14 2021-05-25 The Trustees Of The University Of Pennsylvania Constructs and methods for delivering molecules via viral vectors with blunted innate immune responses
CN114316057B (zh) * 2022-03-14 2022-05-10 深圳市人民医院 一种靶向线粒体外膜转位因子复合体tom20亚基的纳米抗体及其应用
WO2022174834A1 (fr) 2021-02-22 2022-08-25 中国科学院上海药物研究所 Lieur disaccharide, conjugué médicament à petite molécule-disaccharide et conjugué médicament-anticorps à point fixe de chaîne de sucre, leur procédé de préparation et leur utilisation
WO2022180242A2 (fr) * 2021-02-26 2022-09-01 Forschungsverbund Berlin E.V. Absorption cellulaire de grandes biomolécules permise par des additifs peptidiques de pénétration cellulaire réactifs à la surface cellulaire
EP4233882A1 (fr) * 2020-10-22 2023-08-30 Paean Biotechnology Inc. Mitochondries comprenant un médicament anticancéreux et utilisation associée
WO2023173121A1 (fr) 2022-03-11 2023-09-14 Firefly Bio, Inc. Lieurs à base de phényl maléimide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL97459A0 (en) 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CA2604032C (fr) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US20210032369A1 (en) * 2018-02-12 2021-02-04 The Scripps Research Institute Methods related to parkinson?s disease and synucleinopathies
SG11202013176VA (en) * 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
US20260116990A1 (en) * 2022-11-23 2026-04-30 Key2Brain Ab Vhh antibodies and uses thereof
CN116178558B (zh) * 2023-03-28 2025-02-18 山西纳安生物科技股份有限公司 靶向组织因子的纳米抗体及其制备方法和应用

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5122368A (en) 1988-02-11 1992-06-16 Bristol-Myers Squibb Company Anthracycline conjugates having a novel linker and methods for their production
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5824805A (en) 1995-12-22 1998-10-20 King; Dalton Branched hydrazone linkers
WO2003076567A2 (fr) 2002-03-05 2003-09-18 Eli Lilly And Company Proteines hybrides g-csf heterologues
WO2004010957A2 (fr) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
US20060074008A1 (en) 2002-07-31 2006-04-06 Senter Peter D Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20050238649A1 (en) 2003-11-06 2005-10-27 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005077042A2 (fr) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US20060024317A1 (en) 2004-05-19 2006-02-02 Medarex, Inc Chemical linkers and conjugates thereof
US20130266570A1 (en) * 2012-03-30 2013-10-10 Richard H. Weisbart Targeting Intracellular Target-binding Determinants with Intracellular Antibodies
US11015210B2 (en) 2013-03-14 2021-05-25 The Trustees Of The University Of Pennsylvania Constructs and methods for delivering molecules via viral vectors with blunted innate immune responses
EP3786177A1 (fr) * 2018-04-26 2021-03-03 Paean Biotechnology Inc. Mitochondries modifiée et utilisation associée
US20200181578A1 (en) 2018-10-09 2020-06-11 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
EP4233882A1 (fr) * 2020-10-22 2023-08-30 Paean Biotechnology Inc. Mitochondries comprenant un médicament anticancéreux et utilisation associée
WO2022174834A1 (fr) 2021-02-22 2022-08-25 中国科学院上海药物研究所 Lieur disaccharide, conjugué médicament à petite molécule-disaccharide et conjugué médicament-anticorps à point fixe de chaîne de sucre, leur procédé de préparation et leur utilisation
WO2022180242A2 (fr) * 2021-02-26 2022-09-01 Forschungsverbund Berlin E.V. Absorption cellulaire de grandes biomolécules permise par des additifs peptidiques de pénétration cellulaire réactifs à la surface cellulaire
WO2023173121A1 (fr) 2022-03-11 2023-09-14 Firefly Bio, Inc. Lieurs à base de phényl maléimide
CN114316057B (zh) * 2022-03-14 2022-05-10 深圳市人民医院 一种靶向线粒体外膜转位因子复合体tom20亚基的纳米抗体及其应用

Non-Patent Citations (65)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", vol. 51, 2005, LIPPINCOTT WILLIAMS & WILKINS
"Uniprot", Database accession no. 20220222
AHN ET AL., BIOMACROMOLECULES, vol. 21, no. 9, 2020, pages 3539 - 3546
AMORIM JA ET AL., NATURE REVIEWS ENDOCRINOLOGY, vol. 18, 2022, pages 243 - 258
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
BAUER ET AL., NATURE PROTOCOLS, CLICK CHEMISTRY: A TRANSFORMATIVE TECHNOLOGY IN NUCLEAR MEDICINE, vol. 18, 2023, pages 1659 - 1668
BRAUCHLE MICHAEL ET AL: "Protein interference applications in cellular and developmental biology using DARPins that recognize GFP and mCherry", BIOLOGY OPEN, vol. 3, no. 12, 21 November 2014 (2014-11-21), pages 1252 - 1261, XP093338508, ISSN: 2046-6390, Retrieved from the Internet <URL:https://journals.logists.com/bio/bio/article-pdf/3/12/1252/2113160/bio-03-12-1252.pdf> DOI: 10.1242/bio.201410041 *
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CHEN ET AL.: "Rapid Immunopurification of Mitochondria for Metabolite Profiling and Absolute Quantification of Matrix Metabolites", NATURE PROTOCOLS, vol. 21, 2017, pages 2215 - 2231
CORREIZ-MELO, C. ET AL., NAT. PROTOC, vol. 12, 2017, pages 183 - 194
DINGUS ET AL., ELIFE, vol. 11, 2022, pages 68253
DOMENGERGRIMM, HUMAN MOLECULAR GENETICS, vol. 28, 2019, pages 1 - 12
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123
FANTIN VALERIA R. ET AL: "A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells", CANCER RESEARCH, vol. 65, no. 15, 1 August 2005 (2005-08-01), pages 6891 - 6900, XP093339182, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-0395 *
GOLDSTEIN DA: "Clinical Methods: The History, Physical, and Laboratory Examinations", 1990, article "Serum Calcium"
GOSSEN ET AL., SCIENCE, vol. 268, 1995, pages 1766 - 1769
GUSIC MPROKISH J, FEBS LETTERS, vol. 595, no. 8, 2021, pages 1132 - 1158
GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44
HARVEY ET AL., CURR. OPIN. CHEM. BIOL., vol. 2, 1998, pages 512 - 518
HERMANSON, GREG, BIOCONJUGATE TECHNIQUES, 2013
HOLZ, EMILY ET AL., PHARMACEUTICS, vol. 15, 2023, pages 600
ISHIKAWA T ET AL., J CONTROL RELEASE, vol. 274, 2018, pages 109 - 117
JANG Y-H ET AL., PHARMACEUTICS, vol. 13, 2021, pages 810
JOHNSON ET AL., ANTICANCER RES, vol. 15, 1995, pages 1387 - 93
KENNETH, A ET AL.: "Pharmacokinetc analysis: A Practical Approach", CHEMICAL STABILITY OF PHARMACEUTICALS: A HANDBOOK FOR PHARMACISTS AND IN PETERS, 1996
KIM JI SOO ET AL: "Mitochondrial transplantation: an overview of a promising therapeutic approach", BMB REPORTS, vol. 56, no. 9, 11 September 2023 (2023-09-11), pages 488 - 495, XP093339271, ISSN: 1976-670X, DOI: 10.5483/BMBRep.2023-0098 *
KING, MPATTARDI, G., SCIENCE, vol. 246, no. 4929, 1989, pages 500 - 503
KONTERMANN R E ET AL: "INTRACELLULAR AND CELL SURFACE DISPLAYED SINGLE-CHAIN DIABODIES", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 226, no. 1/02, 1 January 1999 (1999-01-01), pages 179 - 188, XP000914688, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(99)00062-9 *
KOZHUKHAR N.ALEXEYEV, M.F., DNA, vol. 4, 2024, pages 201 - 211
KRISTIAN: "Isolation of Mitochondria from CNS", CURR PROTOC NEUROSCI, 2010
LAU ET AL., BIOORG-MED-CHEM, vol. 3, no. 10, 1995, pages 1305 - 12
LAU ET AL., BIOORG-MED-CHEM., vol. 3, no. 10, 1995, pages 1299 - 1304
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
LIU CHIN-SAN ET AL: "Delivering healthy mitochondria for the therapy of mitochondrial diseases and beyond", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 53, 16 May 2014 (2014-05-16), pages 141 - 146, XP029040295, ISSN: 1357-2725, DOI: 10.1016/J.BIOCEL.2014.05.009 *
LIU ET AL., CNS NEUROSCI THER., vol. 27, no. 7, July 2021 (2021-07-01), pages 733 - 742
LUO ET AL., RSC CHEM. BIOL., vol. 3, no. 83018, 2022, pages 19
M GIBALDID PERRON: "Pharmacokinetics", 1982, MARCEL DEKKER
MA ET AL., FRONT IMMUNOL, vol. 14, 2023, pages 131013022 - 24
MADSEN ET AL., FRONT. BIOENG. BIOTECHNOL., vol. 12, 2024, pages 135201435
MCCARTY ET AL., GENE THERAPY, vol. 16, 2001, pages 1248 - 54
NEVILLE ET AL., BIOL. CHEM., vol. 264, 1989, pages 14653 - 14661
NUTTALL S D ET AL: "Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70", EUROPEAN JOURNAL OF BIOCHEMISTRY, PUBLISHED BY SPRINGER-VERLAG ON BEHALF OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES, HOBOKEN, USA, vol. 270, no. 17, 1 September 2003 (2003-09-01), pages 3543 - 3554, XP003013540, ISSN: 0014-2956, DOI: 10.1046/J.1432-1033.2003.03737.X *
PIHL ET AL., NAT REV CHEM, vol. 7, no. 4, 2023, pages 234 - 25534
PIN-CHAO LIAO ET AL.: "Isolation of Mitochondria from Cells and Tissues", METHODS CELL BIOL, vol. 155, 2020, pages 3 - 31
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
SCHNEIDER ANSELM F L ET AL: "Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives", NATURE CHEMISTRY, NATURE PUBLISHING GROUP UK, LONDON, vol. 13, no. 6, 15 April 2021 (2021-04-15), pages 530 - 539, XP037470253, ISSN: 1755-4330, [retrieved on 20210415], DOI: 10.1038/S41557-021-00661-X *
SEIBEL P ET AL., NUCLEIC ACIDS RES., vol. 23, no. 1, 1995, pages 10 - 17
SERAFINI ET AL., ADVANCES IN HETEROCYCLIC CHEMISTRY, 2021
SEVY ET AL., PROTEIN ENG. DES. SEL., vol. 33, 2020, pages 028
SPADAFORA D ET AL., PLOS ONE, vol. 11, no. 5, 2016
SRIVASTAVA S., GENES, vol. 8, no. 12, 19 December 2017 (2017-12-19), pages 398
STENTON SLPROKISCH H., EBIOMEDICINE, vol. 56, 2020, pages 102784
TAKAYAMA ET AL., MOLECULES, vol. 24, no. 1, 2019, pages 172
THORPE ET AL., CANCER RES., vol. 47, 1987, pages 5924 - 5931
TRAENKLE ET AL., FRONTIERS IN IMMUNOLOGY, vol. 12, 2021
VAZQUES-LOMBARDI ET AL., DRUG DISCOVERY TODAY, vol. 20, no. 10, 2015, pages 1271
WALKON LL ET AL., BIOMOLECULES, vol. 12, no. 12, 2022, pages 1891
WAWRZYNCZAK ET AL.: "In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer", 1987, OXFORD U. PRESS
Y. A. MEDVEDEVA ET AL., BIOINFORMATICS-TRENDS AND METHODOLOGIES, vol. 449-472, 2011
YIN ET AL., MABS, vol. 4, 2012, pages 217 - 225
ZHOU ET AL.: "Protocol for Mitochonrial Isolation and SubCellular Localization Assay for Mitochondrial Proteins", STAR PROTOC, vol. 4, no. 1, 2023, pages 102088
ZHU ET AL., NATURE COMMUNICATIONS, vol. 15, 2024
ZIMMERMANN ET AL., ELIFE, vol. 7, 2018, pages 34317
ZIMMERMANN ET AL.: "Generation of synthetic nanobodies against delicate proteins", NAT. PROTOC., vol. 15, 2020, pages 1707 - 1741, XP037111835, DOI: 10.1038/s41596-020-0304-x

Also Published As

Publication number Publication date
WO2026042012A1 (fr) 2026-02-26

Similar Documents

Publication Publication Date Title
AU2020200962B2 (en) Protein modification of living cells using sortase
Jilani et al. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
US20220010337A1 (en) Targeted active gene editing agent and methods of use
JP2024038225A (ja) Ｃａｒ－ｔ細胞及び自己免疫疾患
KR20200021069A (ko) Cd38 조정 항체
CN114126626A (zh) 多特异性结合蛋白
US20220002695A1 (en) Targeted active gene editing agent and methods of use
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
TWI876227B (zh) 多特異性抗體及其藥物用途
CN116323948A (zh) Cd22结合分子及其用途
WO2026042013A1 (fr) Thérapie mitochondriale
Qi et al. Optimal Structural Designs of Trispecific Antibodies to Enhance Therapeutic Efficacy in Solid Tumors and Hematological Malignancies
TW202346315A (zh) 治療及診斷劑以及其用途
CN117295767A (zh) 针对wnt受体ryk的抗体变体
Yang et al. Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
TW202517141A (zh) 生產抗體的方法
Ayupov et al. Cell-type-targeted mitochondrial transplantation rescues cell degeneration
TW202509209A (zh) 生產抗體的方法
HK40068271A (en) Targeted active gene editing agent and methods of use
KR20250143301A (ko) 항-넥틴4 키메라 항원 수용체를 갖는 유전자 조작 세포 및 이의 용도
CN120322465A (zh) 抗gpnmb嵌合抗原受体及其使用方法
CN117813110A (zh) 用于在细胞治疗中使用的可辨别细胞表面蛋白变体
WO2020241827A1 (fr) Cellules exprimant un récepteur antigénique chimérique pour cibler la kinase alk
KR20200019669A (ko) Cd38 조정 항체

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25765044

Country of ref document: EP

Kind code of ref document: A1